Federal contract award
75N91018F00003
AWARD OF TASK ORDER 3 ENTITLED "A DUAL AKT/PDPK1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS"
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541711 |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | HHSN261201500026I |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $2.3M |
| Current contract value | $2.3M |
| Potential contract value / ceiling | $2.3M |
| Start date | Sep 17, 2018 |
| Current end date | Jul 30, 2026 |
| Potential end date | Jul 30, 2026 |
| Latest award activity | May 29, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 20 of 20 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 29, 2026 | P00019 | $0 | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Mar 26, 2026 | P00018 | $0 | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Dec 16, 2025 | P00017 | $0 | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| May 29, 2025 | P00016 | $0 | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Jan 14, 2025 | P00015 | $0 | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Jun 7, 2024 | P00014 | $0 | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| May 9, 2024 | P00013 | $-90 | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Dec 12, 2023 | P00012 | $165.7K | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Oct 30, 2023 | P00010 | $0 | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Oct 30, 2023 | P00011 | $0 | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Aug 30, 2023 | P00009 | $-30.2K | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Feb 15, 2023 | P00008 | $0 | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Dec 14, 2022 | P00007 | $0 | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Aug 12, 2022 | P00006 | $0 | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Dec 17, 2021 | P00005 | $13.9K | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Jun 9, 2021 | P00004 | $0 | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS; 9/17/2018 - 12/16/2022 |
| Aug 28, 2020 | P00003 | $408.8K | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS; 9/17/2018 - 06/16/2021 |
| Jan 31, 2020 | P00002 | $17.0K | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS |
| Jun 24, 2019 | P00001 | $451 | ADD TRAVEL FUNDS TO TASK ORDER 3 ENTITLED "A DUAL AKT/PDPK1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS" |
| Sep 17, 2018 | 0 | $1.7M | AWARD OF TASK ORDER 3 ENTITLED "A DUAL AKT/PDPK1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS" |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.